Concise review: Bone marrow-derived mesenchymal stem cells change phenotype following in vitro culture: Implications for basic research and the clinic

Stem Cells

Volumn 32, Issue 7, 2014, Pages 1713-1723

  Bara, Jennifer J ^a   Richards, R Geoff ^a   Alini, Mauro ^a   Stoddart, Martin J ^a  

^a AO RESEARCH INSTITUTE   (Switzerland)

Author keywords

Bone marrow; Cell culture; Cell therapy; Cell transplantation; Mesenchymal stem cells; Stromal cells

Indexed keywords

5' NUCLEOTIDASE; ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; ADAPALENE; CD146 ANTIGEN; ENDOGLIN; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; HERMES ANTIGEN; NESTIN; PLATELET DERIVED GROWTH FACTOR BB; STEM CELL ANTIGEN 1; THY 1 ANTIGEN; VASCULAR CELL ADHESION MOLECULE 1; DIFFERENTIATION ANTIGEN;

BASIC RESEARCH; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CELL CULTURE; CELL DENSITY; CELL INTERACTION; HEMATOPOIETIC STEM CELL; HUMAN; MESENCHYMAL STEM CELL; NONHUMAN; PERICYTE; PHENOTYPE; PROTEIN EXPRESSION; REVIEW; STEM CELL EXPANSION; STEM CELL NICHE; ANIMAL; CULTURE TECHNIQUE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; METABOLISM; MONONUCLEAR CELL; PHYSIOLOGY; STEM CELL RESEARCH;

ANIMALS; ANTIGENS, DIFFERENTIATION; CELL CULTURE TECHNIQUES; CELLS, CULTURED; HUMANS; LEUKOCYTES, MONONUCLEAR; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; PERICYTES; PHENOTYPE; STEM CELL NICHE; STEM CELL RESEARCH;

EID: 84902577317     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.1649     Document Type: Review

References (136)

1. Friedenstein AJ, Chailakhjan RK, Lalykina KS,. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet 1970; 3: 393-403.
2. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143-147.
3. Phinney DG, Prockop DJ,. Concise review: Mesenchymal stem/multipotent stromal cells: The state of transdifferentiation and modes of tissue repair-Current views. Stem Cells 2007; 25: 2896-2902.
4. Da Silva Meirelles L, Caplan AI, Nardi NB,. In search of the in vivo identity of mesenchymal stem cells. Stem Cells 2008; 26: 2287-2299.
5. Augello A, Kurth TB, De Bari C,. Mesenchymal stem cells: A perspective from in vitro cultures to in vivo migration and niches. Eur Cell Mater 2010; 20: 121-133.
6. Méndez-Ferrer S, Michurina TV, Mazloom AR, et al. Mesenchymal and haematpoietic stem cells form a unique bone marrow niche. Nature 2010; 466: 829-834.
7. Ehninger A, Trum PP,. The bone marrow stem cell niche grows up: Mesenchymal stem cells and macrophages move in. J Ex Med 2011; 208: 421-428.
8. Isern J, Méndez-Ferrer S,. Stem cell interactions in a bone marrow niche. Curr Osteoporos Rep 2011; 9: 210-218.
9. Tolar J, Le Blanc K, Keating A, et al. Concise review: Hitting the right spot with mesenchymal stromal cells. Stem Cells 2010; 28: 1446-1455.
10. Rasini V, Dominici M, Kluba T, et al. Mesenchymal stromal/stem cell markers in the human bone marrow. Cytotherapy 2013; 15: 292-306.
11. Calvi LM, Adams GB, Weibrecht KW, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003; 425: 841-846.
12. Osugi M, Katagiri W, Yoshimi R, et al. Conditioned media from mesenchymal stem cells enhanced bone regeneration in rat calvarial bone defects. Tissue Eng Part A 2012; 18: 1479-1489.
13. Taichman RS, Emerson SG,. Human osteoblasts support hematopoiesis through the production of granulocyte colony-stimulating factor. J ExMed 1994; 179: 1677-1682.
14. Taichman S, Reilly MJ, Verma RS, et al. Hepatocyte growth factor is secreted by osteoblasts and cooperatively permits the survival of haematopoietic progenitors. Br J Haematol 2001; 112: 438-448.
15. Arai F, Hirao A, Ohmura M, et al. Tie2/angiopoietin-1 signalling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell 2004; 118: 149-161.
16. Qian H, Buza-Vidas N, Hyland CD, et al. Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells. Cell Stem Cell 2007; 1: 671-684.
17. Yoshihara H, Arai F, Hosokawa K, et al. Thrombopoietin/MPL signalling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche. Cell Stem Cell 2007; 1: 685-697.
18. Jung Y, Song J, Shiozawa Y, et al. Hematopoietic stem cells regulate mesenchymal stromal cell induction into osteoblasts thereby participating in the formation of the stem cell niche. Stem Cells 2008; 26: 2042-2051.
19. Nicolaidou V, Wong MM, Redpath AN, et al. Monocytes induce STAT3 activation in human mesenchymal stem cells to promote osteoblast formation. PLoS One 2012; 7: e39871.
20. Nakamura Y, Arai F, Iwasaki H, et al. Isolation and characterization of endosteal niche cell populations that regulate hematopoietic stem cells. Blood 2010; 116: 1422-1432.
21. Brighton CT, Lorich DG, Kupcha R, et al. The pericyte as a possible osteoblast progenitor cell. Clin Orthop Relat Res 1992; 275: 287-299.
22. Farrington-Rock C, Crofts NJ, Doherty MJ, et al. Chondrogenic and adipogenic potential of microvascular pericytes. Circulation 2004; 110: 2226-2232.
23. Sacchetti B, Funari A, Michienzi S, et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell 2007; 131: 324-336.
24. Crisan M, Yap S, Casteilla L, et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 2008; 3: 301-313.
25. Wright DE, Wagers AJ, Gulati AP, et al. Physiological migration of hematopoietic stem and progenitor cells. Science 2001; 294: 1933-1936.
26. Katayama Y, Battista M, Kao WM, et al. Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. Cell 2006; 124: 407-421.
27. Méndez-Ferrer S, Lucas D, Battista M, et al. Haematopoietic stem cell release is regulated by circadian oscillations. Nature 2008; 452: 442-447.
28. Peled A, Petit I, Kollet O, et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 1999; 283: 845-848.
29. Semerad C.L, Christopher M.J, Liu F, et al. G-CSF potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow. Blood 2005; 106: 3020-3027.
30. Sugiyama T, Kohara H, Noda M, et al. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signalling in bone marrow stromal cell niches. Immunity 2006; 25: 977-988.
31. Greenbaum A, Hsu Y-MS, Day RB, et al. CXCL12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenance. Nature 2013; 495: 227-231.
32. Corselli M, Chin CJ, Parekh C, et al. Perivascular support of human hematopoietic stem/progenitor cells. Blood 2013; 121: 2891-2901.
33. Ozerdem U, Monosov E, Stallcup WB,. NG2 proteoglycan expression by pericytes in pathological microvasculature. Microvasc Res 2002; 63: 129-134.
34. Hellström M, Kalén M, Lindahl P, et al. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 1999; 126: 3047-3055.
35. Li Q, Yu Y, Bischoff J, et al. Differential expression of CD146 in tissues and endothelial cells derived from infantile haemangioma and normal human skin. J Pathol 2003; 201: 296-302.
36. Blocki A, Wang Y, Koch M, et al. Not all MSCs can act as pericytes: Functional in vitro assays to distinguish pericytes from other mesenchymal stem cells in angiogenesis. Stem Cells Dev 2013; 22: 1-9.
37. Schächinger V, Tonn T, Dimmeler S, et al. Bone-marrow-derived progenitor cell therapy in need of proof of concept: Design of the REPAIR-AMI trial. Nat Clin Pract Cardiovasc Med 2006; 3 (suppl 1): 23-28.
38. Lunde K, Solheim S, Aakhus S, et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med 2006; 355: 1199-1209.
39. Seeger FH, Tonn T, Krzossok N, et al. Cell isolation procedures matter: A comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infarction. Eur Heart J 2007; 28: 766-772.
40. van Beem RT, Hirsch A, Lommerse IM, et al. Recovery and functional activity of mononuclear bone marrow and peripheral blood cells after different cell isolation protocols used in clinical trials for cell therapy after acute myocardial infarction. EuroIntervention 2008; 4: 133-138.
41. Mouquet F, Lemesle G, Delhaye C, et al. The presence of apoptotic bone marrow cells impairs the efficacy of cardiac cell therapy. Cell Transplant 2011; 20: 1087-1097.
42. Assmus B, Tonn T, Seeger FH, et al. Red blood cell contamination of the final cell product impairs the efficacy of autologous bone marrow mononuclear cell therapy. J Am Coll Cardiol 2010; 55: 1385-1394.
43. Mareschi K, Rustichelli D, Calabrese R, et al. Multipotent mesenchymal stromal stem cell expansion by plating whole bone marrow at a low cellular density: A more advantageous method for clinical use. Stem Cells Int 2012; e920581.
44. Pösel C, Möller K, Fröhlich W, et al. Density gradient centrifugation compromises bone marrow mononuclear cell yield. PLoS One 2012; 7: e50293.
45. Wan C, He Q, McCaigue M, et al. Nonadherent cell population of human marrow culture is a complementary source of mesenchymal stem cells (MSCs). J Orthop Res 2006; 24: 21-28.
46. Zhang ZL, Tong J, Lu RN, et al. Therapeutic potential of non-adherent BM-derived mesenchymal stem cells in tissue regeneration. Bone Marrow Transplant 2009; 43: 69-81.
47. Akiyama K, You YO, Yamaza T, et al. Characterization of bone marrow derived mesenchymal stem cells in suspension. Stem Cell Res Therap 2012; 3: 40.
48. Di Maggio N, Mehrkens A, Papadimitropoulos A, et al. Fibroblast growth factor-2 maintains a niche-dependent population of self-renewing highly potent non-adherent mesenchymal progenitors through FGFR2c. Stem Cells 2012; 30: 1455-1464.
49. Digirolamo CM, Stokes D, Colter D, et al. Propagation and senescence of human marrow stromal cells in culture: A simple colony-forming assay identifies samples with the greatest potential to propagate and differentiate. Brit J Haematol 1999; 107: 275-281.
50. Muraglia A, Cancedda R, Quarto R,. Clonal mesenchymal progenitors from human bone marrow differentiate in vitro according to a hierarchical model. J Cell Sci 2000; 113(Pt 7): 1161-1166.
51. Bruder SP, Jaiswal N, Haynesworth SE,. Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation. J Cell Biochem 1997; 64: 278-294.
52. Baxter MM, Wynn R.F, Jowitt SN, et al. Study of telomere length reveals rapid aging of human marrow stromal cells following in vitro expansion. Stem Cells 2004; 22: 675-682.
53. Dexheimer V, Mueller S, Braatz F, et al. Reduced reactivation from dormancy but maintained lineage choice of human mesenchymal stem cells with donor age. PLoS One 2011; 6: e22980.
54. Fennema EM, Renard AJ, Leusink A, et al. The effect of bone marrow aspiration strategy on the yield and quality of human mesenchymal stem cells. Acta Orthop 2009; 80: 618-621.
55. Redaelli S, Bentivegna A, Foudah D, et al. From cytogenomic to epigenomic profiles: Monitoring the biologic behaviour of in vitro cultured human bone marrow mesenchymal stem cells. Stem Cell Res Ther 2012; 3: 47.
56. Banfi A, Bianchi G, Notaro R, et al. Replicative aging and gene expression in long-term cultures of human bone marrow stromal cells. Tissue Eng 2002; 8: 901-910.
57. Bork S, Pfister S, Witt H, et al. DNA methylation pattern changes upon long-term culture and aging of human mesenchymal stromal cells. Aging Cell 2010; 9: 54-63.
58. Wagner W, Horn P, Castoldi M, et al. Replicative senescence of mesenchymal stem cells: A continuous and organized process. PLoS One 2008; 3: e2213.
59. Fekete N, Rojewski MT, Fürst D, et al. GMP-compliant isolation and large-scale expansion of bone marrow-derived MSC. PLoS One 2012; 7: e43255.
60. Qian H, Le Blanc K, Sigvardsson M,. Primary mesenchymal stem and progenitor cells from bone marrow lack expression of CD44 protein. J Biol Chem 2012; 287: 25795-25807.
61. Both SK, Van der Muijsenberg AJC, Van Blitterswijk CA, et al. A rapid and efficient method for expansion of human mesenchymal stem cells. Tissue Eng 2007; 13: 3-9.
62. Bartmann C, Rohde E, Schallmoser K, et al. Two steps to functional mesenchymal stromal cells for clinical application. Transfusion 2007; 47: 1426-1435.
63. Neuhuber B, Swanger SA, Howard L, et al. Effects of plating density and culture time on bone marrow stromal cell characteristics. Exp Hematol 2008; 36: 1176-1185.
64. Tonti GA, Mannello F,. From bone marrow to therapeutic applications: Different behaviour and genetic/epigenetic stability during mesenchymal stem cell expansion in autologous and foetal bovine sera? Int J Dev Biol 2009; 52: 1023-1032.
65. Shahdadfar A, Frønsdal K, Haug T, et al. In vitro expansion of human mesenchymal stem cells: Choice of serum is a determinant of cell proliferation, differentiation, gene expression, and transcriptome stability. Stem Cells 2005; 23: 1357-1366.
66. Wappler J, Rath B, Läufer T, et al. Eliminating the need of serum testing using low serum culture conditions for human bone marrow-derived mesenchymal stromal cell expansion. Biomed Eng Online 2013; 20: 12-15.
67. Vogel JP, Szalay K, Geiger F, et al. Platelet-rich plasma improves expansion of human mesenchymal stem cells and retains differentiation capacity and in vivo bone formation in calcium phosphate ceramics. Platelets 2006; 17: 462-469.
68. Mishra A, Tummala P, King A, et al. Buffered platelet-rich plasma enhances mesenchymal stem cell proliferation and chondrogenic differentiation. Tissue Eng Part C Methods 2009; 15: 431-435.
69. Goedecke A, Wobus M, Krech M, et al. Differential effect of platelet-rich plasma and fetal calf serum on bone marrow-derived human mesenchymal stromal cells expanded in vitro. J Tissue Eng Regen Med 2011; 5: 648-654.
70. Bieback K, Hecker A, Kocaömer A, et al. Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow. Stem Cells 2009; 27: 2331-2341.
71. Schallmoser K, Bartmann C, Rohde E, et al. Replicative senescence-associated gene expression changes in mesenchymal stromal cells are similar under different culture conditions. Haematologica 2010; 95: 867-874.
72. Azouna BN, Jenhani F, Regaya Z, et al. Phenotypical and functional characteristics of mesenchymal stem cells from bone marrow: Comparison of culture using different media supplemented with human platelet lysate or fetal bovine serum. Stem Cell Res Ther 2012; 3: 6.
73. Fekete N, Rojewski MT, Lotfi R, et al. Essential components for ex vivo proliferation of mesenchymal stromal cells. Tissue Eng Part C Methods 2013. [Epub ahead of print].
74. Lohmann M, Walenda G, Hemeda H, et al. Donor age of human platelet lysate affects proliferation and differentiation of mesenchymal stem cells. PLoS One 2012; 7: e37839.
75. Tarte K, Gaillard J, Lataillade JJ, et al. Clinical-grade production of human mesenchymal stromal cells: Occurrence of aneuploidy without transformation. Blood 2010; 115: 1549-1553.
76. Martin I, Muraglia A, Campanile G, et al. Fibroblast growth factor-2 supports ex vivo expansion and maintenance of osteogenic precursors from human bone marrow. Endocrinology 1997; 138: 4456-4462.
77. Bianchi G, Banfi A, Mastrogiacomo M, et al. Ex vivo enrichment of mesenchymal cell progenitors by fibroblast growth factor 2. Exp Cell Res 2003; 287: 98-105.
78. Solchaga LA, Penick K, Porter JD, et al. FGF-2 enhances the mitotic and chondrogenic potentials of human adult bone marrow-derived mesenchymal stem cells. J Cell Physiol 2005; 203: 398-409.
79. Bocelli-Tyndall C, Zajac P, Di Maggio N, et al. Fibroblast growth factor 2 and platelet-derived growth factor, but not platelet lysate, induce proliferation-dependent, functional class II major histocompatibility complex antigen in human mesenchymal stem cells. Arthritis Rheum 2010; 62: 3815-3825.
80. Gharibi B, Hughes FJ,. Effects of medium supplements on proliferation, differentiation potential, and in vitro expansion of mesenchymal stem cells. Stem Cells Transl Med 2012; 1: 771-782.
81. Barry F, Boynton R, Murphy M, et al. The SH-3 and SH-4 antibodies recognize distinct epitopes on CD73 from human mesenchymal stem cells. Biochem Biophys Res Commun 2001; 289: 519-524.
82. Barry FP, Boynton RE, Haynesworth S, et al. The monoclonal antibody SH-2, raised against human mesenchymal stem cells, recognises an epitope on endoglin (CD105). Biochem Biophys Res Commun 1999; 265: 134-139.
83. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-317.
84. Stewart K, Monk P, Walsh S, et al. STRO-1, HOP-26 (CD63), CD49a and SB-10 (CD166) as markers of primitive human marrow stromal cells and their more differentiated progeny: A comparative investigation in vitro. Cell Tissue Res 2003; 313: 281-290.
85. Jones EA, English A, Kinsey SE, et al. Optimization of a flow cytometry-based protocol for detection and phenotypic characterization of multipotent mesenchymal stromal cells from human bone marrow. Cytometry B Clin Cytom 2006; 70: 391-399.
86. Simmons PJ, Torok-Storb B,. Identification of stromal cell precursors in human bone marrow by a novel monocloncal antibody, STRO-1. Blood 1991; 78: 55-62.
87. Gronthos S, Zannettino AC, Hay SJ, et al. Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow. J Cell Sci 2003; 116 (Pt 9): 1827-1835.
88. Whitney MJ, Lee A, Ylostalo J, et al. Leukaemia inhibitory factor secretion is a predictor and indicator of early progenitor status in adult bone marrow stromal cells. Tissue Eng: Part A 2009; 15: 33-44.
89. Halfon S, Abramov N, Grinblat B, et al. Markers distinguishing mesenchymal stem cells from fibroblasts are downregulated with passaging. Stem Cells Dev 2011; 20: 53-66.
90. Martinez C, Hofmann TJ, Marino R, et al. Human bone marrow mesenchymal stromal cells express the neural ganglioside GD2: A novel surface marker for the identification of MSCs. Blood 2007; 109: 4245-4248.
91. Morikawa S, Mabuchi Y, Kubota Y, et al. Prospective identification, isolation, and systemic transplantation of multipotent mesenchymal stem cells in murine bone marrow. J Exp Med 2009; 206: 2483-24896.
92. Quarto R, Mastrogiacomo M, Cancedda R, et al. Repair of large bone defects with the use of autologous bone marrow stromal cells. N Engl J Med 2001; 344: 385-386.
93. Marcacci M, Kon E, Moukhachev V, et al. Stem cells associated with macroporous bioceramics for long bone repair: 6- to 7-year outcome of a pilot clinical study. Tissue Eng 2007; 13: 947-955.
94. Bajada S, Harrison PE, Ashton BA, et al. Successful treatment of refractory tibial nonunion using calcium sulphate and bone marrow stromal cell implantation. J Bone Joint Surg Br 2007; 89: 1382-1386.
95. Kuroda R, Ishida K, Matsumoto T, et al. Treatment of a full-thickness articular cartilage defect in the femoral condyle of an athlete with autologous bone-marrow stromal cells. Osteoarthritis Cartilage 2007; 15: 226-231.
96. Nejadnik H, Hui JH, Feng Choong E, et al. Autologous bone marrow-derived mesenchymal stem cells versus autologous chondrocyte implantation: An observational cohort study. Am J Sports Med 2010; 38: 1110-1116.
97. Wakitani S, Okabe T, Horibe S, et al. Safety of autologous bone marrow-derived mesenchymal stem cell transplantation for cartilage repair in 41 patients with 45 joints followed up to 11 years and 5 months. J Tissue Eng Regen Med 2011; 5: 146-150.
98. Ge J, Li Y, Qian J, et al. Efficacy of emergent transcatheter transplantation of stem cells for treatment of acute myocardial infarction (TCT-STAMI). Heart 2006; 92: 1764-1767.
99. Williams AR, Trachtenberg B, Velazquez DL, et al. Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: Functional recovery and reverse remodeling. Circulation Res 2011; 108: 792-796.
100. Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs. autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: The POSEIDON randomized trial. JAMA 2012; 308: 2369-2379.
101. Saito F, Nakatani T, Iwase M, et al. Spinal cord injury treatment with intrathecal autologous bone marrow stromal cell transplantation: The first clinical trial case report. J Trauma 2008; 64: 53-59.
102. Pal R, Venkataramana NK, Bansal A, et al. Ex vivo-expanded autologous bone marrow-derived mesenchymal stromal cells in human spinal cord injury/paraplegia: A pilot clinical study. Cytotherapy 2009; 11: 897-911.
103. Karamouzian S, Nematollahi-Mahani SN, Nakhaee N, et al. Clinical safety and primary efficacy of bone marrow mesenchymal cell transplantation in subacute spinal cord injured patients. Clin Neurol Neurosurg 2012; 114: 935-939.
104. Hermann PC, Huber SL, Herrler T, et al. Concentration of bone marrow total nucleated cells by a point-of-care device provides a high yield and preserves their functional activity. Cell Transplantation 2008; 16: 1059-1069.
105. Gangji V, Hauzeur JP, Matos C, et al. Treatment of osteonecrosis of the femoral head with implantation of autologous bone-marrow cells. A pilot study. J Bone Joint Surg Am 2004; 86-A: 1153-1160.
106. Garg NK, Gaur S, Sharma S,. Percutaneous autogenous bone marrow grafting in 20 cases of ununited fracture. Acta Orthop Scand 1993; 64: 671-672.
107. Connolly JF,. Injectable bone marrow preparations to stimulate osteogenic repair. Clin Orthop Relat Res 1995; 313: 8-18.
108. Hernigou P, Poignard A, Manicom O, et al. The use of percutaneous autologous bone marrow transplantation in nonunion and avascular necrosis of bone. J Bone Joint Surg Br 2005; 87: 896-902.
109. Jäger M, Jelinek EM, Wess KM, et al. Bone marrow concentrate: A novel strategy for bone defect treatment. Curr Stem Cell Res Ther 2009; 4: 34-43.
110. Gan Y, Dai K, Zhang P, et al. The clinical use of enriched bone marrow stem cells combined with porous beta-tricalcium phosphate in posterior spinal fusion. Biomaterials 2008; 29: 3973-3982.
111. Kretlow JD, Spicer PP, Jansen JA, et al. Uncultured marrow mononuclear cells delivered within fibrin glue hydrogels to porous scaffolds enhance bone regeneration within critical-sized rat cranial defects. Tissue Eng Part A 2010; 16: 3555-3568.
112. Fortier LA, Potter HG, Rickey EJ, et al. Concentrated bone marrow aspirate improves full-thickness cartilage repair compared with microfracture in the equine model. J Bone Joint Surg Am 2010; 92: 1927-1937.
113. Bekkers JE, Creemers LB, Tsuchida AI, et al. One-stage focal cartilage defect treatment with bone marrow mononuclear cells and chondrocytes leads to better macroscopic cartilage regeneration compared to microfracture in goats. Osteoarthritis Cartilage 2013; 21: 950-956.
114. Assmus B, Walter DH, Seeger FH, et al. Effect of shock wave-facilitated intracoronary cell therapy on LVEF in patients with chronic heart failure: The CELLWAVE randomized clinical trial. JAMA 2013; 309: 1622-1631.
115. Sürder D, Manka R, Lo Cicero V, et al. Intracoronary injection of bone marrow-derived mononuclear cells early or late after acute myocardial infarction: Effects on global left ventricular function. Circulation 2013; 127: 1968-1979.
116. Traverse JH, Henry TD, Pepine CJ, et al. Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: The TIME randomized trial. JAMA 2012; 308: 2380-2389.
117. Rodrigo SF, van Ramshorst J, Beeres SL, et al. Intramyocardial injection of bone marrow mononuclear cells in chronic myocardial ischemia patients after previous placebo injection improves myocardial perfusion and anginal symptoms: An intra-patient comparison. Am Heart J 2012; 164: 771-778.
118. Perin EC, Willerson JT, Pepine CJ, et al. Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: The FOCUS-CCTRN trial. JAMA 2012; 307: 1717-1726.
119. Iwase T, Nagaya N, Fujii T, et al. Comparison of angiogenic potency between mesenchymal stem cells and mononuclear cells in a rat model of hindlimb ischemia. Cardiovasc Res 2005; 66: 543-551.
120. Lu D, Chen B, Liang Z, et al. Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: A double-blind, randomized, controlled trial. Diabetes Res Clin Pract 2011; 92: 26-36.
121. Otsuru S, Gordon PL, Shimono K, et al. Transplanted bone marrow mononuclear cells and MSCs impart clinical benefit to children with osteogenesis imperfecta through different mechanisms. Blood 2012; 120: 1933-1941.
122. Di Maggio N, Piccinini E, Jamorski M, et al. Toward modelling the bone marrow niche using scaffold-based 3D culture systems. Biomaterials 2011; 32: 321-329.
123. Sart S, Tsai AC, Li Y, et al. Three-dimensional aggregates of mesenchymal stem cells: Cellular mechanisms, biological properties, and applications. Tissue Eng Part B Rev 2013. [Epub ahead of print].
124. Muraglia A, Corsi A, Riminucci M, et al. Formation of a chondro-osseous rudiment in micromass cultures of human bone-marrow stromal cells. J Cell Sci 2003; 116: 2949-2955.
125. Potapova IA, Brink PR, Cohen IS, et al. Culturing of human mesenchymal stem cells as three-dimensional aggregates induces functional expression of CXCR4 that regulates adhesion to endothelial cells. J Biol Chem 2008; 283: 13100-13107.
126. Bartosh TJ, Ylöstalo JH, Mohammadipoor A, et al. Aggregation of human mesenchymal stromal cells (MSCs) into 3D spheroids enhances their antiinflammatory properties. Proc Natl Acad Sci USA 2010; 107: 13724-13729.
127. Frith JE, Thomson B, Genever PG,. Dynamic three-dimensional culture methods enhance mesenchymal stem cell properties and increase therapeutic potential. Tissue Eng Part C Methods 2010; 16: 735-749.
128. Baraniak PR, McDevitt TC,. Scaffold-free culture of mesenchymal stem cell spheroids in suspension preserves multilineage potential. Cell Tissue Res 2012; 347: 701-711.
129. Ylöstalo JH, Bartosh TJ, Coble K, et al. Human mesenchymal stem/stromal cells cultured as spheroids are self-activated to produce prostaglandin E2 that directs stimulated macrophages into an anti-inflammatory phenotype. Stem Cells 2012; 30: 2283-2296.
130. Braccini A, Wendt D, Jaquiry C, et al. Three-dimensional perfusion culture of human bone marrow cells and generation of osteoinductive grafts. Stem Cells 2005; 23: 1066-1072.
131. Scaglione S, Braccini A, Wendt D, et al. Engineering of osteoinductive grafts by isolation and expansion of ovine bone marrow stromal cells directly on 3D ceramic scaffolds. Biotechnol Bioeng 2006; 93: 181-187.
132. Claros S, Rodríguez-Losada N, Cruz E, et al. Characterisation of adult/progenitor cell populations from bone marrow in a three-dimensional collagen gel culture system. Cell Transplant 2012; 21: 2021-2032.
133. Chattergea A, Renard AJS, Jolink C, et al. Streamlining the generation of an osteogenic graft by 3D culture of unprocessed bone marrow on ceramic scaffolds. J Tissue Eng Regen Med 2012; 6: 103-112.
134. Ventura Ferreira MS, Jahnen-Dechent W, Labude N, et al. Cord blood-hematopoietic stem cell expansion in 3D fibrin scaffolds with stromal support. Biomaterials 2012; 33: 6987-6997.
135. Leisten I, Kramann R, Ventura Ferreira MS, et al. 3D co-culture of hematpoietic stem and progenitor cells and mesenchymal stem cells in collagen scaffolds as a model of the hematpoietic niche. Biomaterials 2012; 33: 1736-1747.
136. Cox SA, Giannoudis PV, et al. High abundance of CD271(+) multipotential stromal cells (MSCs) in intramedullary cavities of long bones. Bone 2012; 50: 510-517.